Compare FTAI Aviation Ltd (FTAI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Summit Therapeutics Inc — how do they compare? FTAI Aviation Ltd trades at $205.75 (market cap $21.93B), while Summit Therapeutics Inc trades at $14.39 (market cap $11.70B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and FTAI Aviation Ltd pays a 0.7% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FTAI | SMMT | |
|---|---|---|
Market Cap | $21.93B | $11.70B |
Sector | Industrials | Health |
52-Week High | $310.04 | $29.32 |
52-Week Low | $109.92 | $13.05 |
Enterprise Value | $24.97B | $11.12B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $205.71, down 0.25% with a bearish technical outlook despite unanimous analyst buy ratings. The company reported strong revenue growth to $2.51 billion in 2025 with 19% net margins, though recent quarters show earnings misses. Positive developments include a strategic Boeing 737-800 freighter collaboration and expansion into data center power solutions, while negative operating cash flow raises execution concerns.
The stock presents growth potential from aerospace servicing and new power segment opportunities, but faces risks from consistent earnings misses and high valuations (P/E 42.6). Institutional sentiment remains strongly positive with 100% buy ratings, though technical indicators suggest near-term pressure with support at $195.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
